Breil et al. reported that cabergoline (initial dose ~0.5 mg/week) normalized PRL levels in eight out of 11 patients (73%) in their series, reduced tumor volume by an average of 80%, and led to clinical improvement in both headache and significant pubertal delay (p = 0.016 and p = 0.031, respectively) [10]. This evidence concerns the gene PRL and neoplasm.